Neither has enough direct comparative clinical research to be declared universally superior
[18] MS patients experiencing worsening neurological symptoms during semaglutide therapy require prompt evaluation to distinguish medication effects from MS disease activity, though the latter is far more likely
Introduction As the popularity of GLP-1 drugs for weight loss soared, the Food and Drug Administration (FDA) began announcing that FDA-approved versions of various GLP-1 drugs were going into shortage, starting with semaglutide (the active ingredient in Wegovy and Ozempic) in March 2022
Dulaglutide is an option when eGFR is above 15 mL/min/1.73 m, but adjustments may be necessary for severe impairment
It supports endurance, metabolism, and recovery while ensuring safety and effectiveness
Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made